low - Pharmaceutical demand is non-discretionary and relatively GDP-insensitive. Generic utilization may increase modestly during recessions as patients and payers seek lower-cost alternatives to branded drugs. However, unemployment affecting insurance coverage and Medicaid enrollment shifts can impact payor mix and reimbursement rates. Teva's international exposure (50% ex-US) provides diversification but introduces emerging market currency volatility.

Rising rates increase financing costs on Teva's $18B debt load (weighted average interest rate ~4.5%), with ~40% floating rate exposure creating $70M+ annual cash flow impact per 100bps rate move. Higher rates also pressure valuation multiples for leveraged healthcare companies. However, Teva benefits from USD strength against shekel and European currencies when rates rise, as ~30% of costs are non-USD denominated. The company's debt refinancing schedule shows $2-3B maturities through 2028, making near-term rate environment critical for interest expense trajectory.

value - Teva attracts deep value investors focused on turnaround potential, debt reduction, and multiple expansion from trough levels. The 186% net income growth reflects recovery from 2020-2022 restructuring losses rather than sustainable expansion. Current 2.3x P/S and 17.1x EV/EBITDA multiples remain below pre-2017 levels (25-30x) when company carried investment-grade rating. Investors are betting on stabilization of generic pricing, Austedo growth offsetting Copaxone decline, and deleveraging driving re-rating. Limited dividend (suspended 2017) and high debt reduce income investor appeal.